{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:02:27Z","timestamp":1791946947418,"version":"4.3.4"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Venetoclax (VNX)-based regimens have demonstrated significantly favorable outcomes in patients with acute myeloid leukemia (AML) and are now becoming the standard treatment. Tyrosine kinase inhibitors are administered at a fixed dose, irrespective of body surface area or weight. For such orally targeted therapies, real-world data have highlighted a larger pharmacokinetic (PK) interindividual variability (IIV) than expected. Even if VNX PKs have been well characterized and described in the literature, only 1 clinical trial\u2013based PK study has been conducted in patients with AML. This study aimed to evaluate the PK of VNX in AML patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods:<\/jats:title>\n                    <jats:p>We retrospectively analyzed all patients treated with a combination of VNX\u2013azacitidine between January and July 2022 at our center, using at least 1 available VNX blood sample. Based on a previously published population PK model, individual PK parameters were estimated to evaluate the exposure and IIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>and Discussion. Twenty patients received VNX in combination with azacitidine, according to the PK data. A total of 93 plasma concentrations were collected. The dose of VNX was 400 mg, except in 7 patients who received concomitant posaconazole (VNX 70 mg). The patients' weight ranged from 49 kg to 108 kg (mean = 78 kg). Mean individual clearance was 13.5 \u00b1 9.4 L\/h with mean individual daily area under the concentration\u2013time curves of 35.8 mg.h\/L with significant IIV (coefficient of variation = 41.1%). Ten patients were still alive (8 in complete response), but all experienced at least 1 hematological toxicity of grade \u2265 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Based on the observed large PK variability in the data from our real-world AML patients, the risk of drug interactions and the recommended fixed-dosage regimen of VNX therapeutic drug monitoring may be useful.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001151","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:30Z","timestamp":1699488030000},"page":"127-131","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetic Consideration of Venetoclax in Acute Myeloid Leukemia Patients: A Potential Candidate for TDM? A Short Communication"],"prefix":"10.1097","volume":"46","author":[{"given":"Michael","family":"Philippe","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Centre Leon Berard, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Guitton","sequence":"additional","affiliation":[{"name":"Biochemistry and Pharmacology-Toxicology Laboratory, Lyon Sud Hospital, Pierre Benite, France;"},{"name":"ISPB, Facult\u00e9 de Pharmacie de Lyon, Universit\u00e9 Lyon 1, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Goutelle","sequence":"additional","affiliation":[{"name":"ISPB, Facult\u00e9 de Pharmacie de Lyon, Universit\u00e9 Lyon 1, Lyon, France;"},{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie, Lyon, France;"},{"name":"UMR CNRS 5558, Laboratoire de Biom\u00e9trie et Biologie Evolutive, Universit\u00e9 Lyon 1, Villeurbanne, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Thoma","sequence":"additional","affiliation":[{"name":"School of Engineering and Management Vaud (HEIG-VD), HES-SO University of Applied Sciences and Arts Western Switzerland, Yverdon-les-Bains, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Favier","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Centre Leon Berard, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Chtiba","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[{"name":"Hematology Department, Centre Leon Berard, Lyon, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Belhabri","sequence":"additional","affiliation":[{"name":"Hematology Department, Centre Leon Berard, Lyon, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hon.2964","article-title":"Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-na\u00efve acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"40","author":"Brackman","year":"2022","journal-title":"Hematol Oncol"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ctrv.2010.08.006","article-title":"Moving towards dose individualization of tyrosine kinase inhibitors","volume":"37","author":"Kl\u00fcmpen","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00228-019-02704-2","article-title":"Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine","volume":"75","author":"Groenland","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/hon.2646","article-title":"Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure-response analysis","volume":"37","author":"Agarwal","year":"2019","journal-title":"Hematological Oncol"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/FTD.0000000000000771","article-title":"Evaluation of imatinib concentrations in samples submitted for BCR-ABL1 or imatinib testing-evidence to support therapeutic drug monitoring for dose optimization?","volume":"42","author":"Smy","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2015.12.029","article-title":"Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting","volume":"57","author":"Bouchet","year":"2016","journal-title":"Eur J Cancer"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/FTD.0000000000000699","article-title":"Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: a critical review","volume":"42","author":"Cardoso","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00432-021-03645-z","article-title":"Real-life drug-drug and herb-drug interactions in outpatients taking oral anticancer drugs: comparison with databases","volume":"148","author":"Prely","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"R13-20250603","doi-asserted-by":"crossref","DOI":"10.1145\/3107411.3107439","article-title":"TUCUXI: an intelligent system for personalized medicine from individualization of treatments to research databases and back","author":"Dubovitskaya","year":"2017"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"e025433\u201318","DOI":"10.1128\/AAC.02543-18","article-title":"External evaluation of population pharmacokinetic models of vancomycin in large cohorts of intensive care unit patients","volume":"63","author":"Guo","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40262-019-00788-8","article-title":"Bayesian population model of the pharmacokinetics of venetoclax in combination with rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia: results from the phase III MURANO study","volume":"58","author":"Deng","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12032-022-01865-y","article-title":"Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia","volume":"39","author":"Kobayashi","year":"2022","journal-title":"Med Oncol"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","article-title":"Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia","volume":"102","author":"Aiba","year":"2023","journal-title":"Ann Hematol"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"E416","DOI":"10.1002\/ajh.26692","article-title":"Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A","volume":"97","author":"Pratz","year":"2022","journal-title":"Am J Hematol"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"E299","DOI":"10.1002\/ajh.26600","article-title":"Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia","volume":"97","author":"Jonas","year":"2022","journal-title":"Am J Hematol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:04:54Z","timestamp":1748955894000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001151","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"2023-02-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}